Ready 8-Ks
50
Latest filing
August 14, 2026, 4:17 PM ET
Top materiality
0.80
Event mix
earnings ×15 · other_material ×13 · m_and_a ×10
Sentiment
14 pos · 0 neg · 36 neu
Latest earnings
▼ miss 2026-Q2
-
US Physical Therapy appoints Nchacha Etta as EVP and CFO effective Sept 1, 2026
Nchacha Etta, 56, former CFO of Omnicell (2023-2025), appointed EVP & CFO effective Sept 1, 2026.
-
USPH Q2 GAAP EPS falls to $0.25 from $0.58; revenue up 8.5%; reaffirms FY guidance
Q2 2026 net revenue $214.1M (+8.5% YoY); GAAP EPS $0.25 vs $0.58; adjusted EBITDA $27.0M vs $26.9M.
-
USPH Q1 revenue $198.3M (+7.9% YoY); GAAP loss $0.12/share, adjusted EBITDA rises to $20.2M
Revenue $198.3M, up 7.9% YoY; GAAP net income $5.0M, loss per share $0.12 vs EPS $0.80 prior year.
-
USPH enters $450M credit facility with $275M revolver and $175M term loan, maturing 2031
New $450M credit facility comprises $275M revolver and $175M term loan, matures April 14, 2031.
-
USPH reports FY2025 Adj. EBITDA $95M (+16%); CFO resigns; dividend raised to $0.46
FY2025 net revenue $781M (+16.3% YoY); Adj. EBITDA $95M (+16.2%); GAAP EPS $1.42 vs $1.84 prior.
-
USPH announces $15.1M acquisition of industrial injury business and 10-year alliance with NYU Langone Health
Acquired 70% of industrial injury prevention business for ~$15.1M; target generates ~$7M in annual revenue.
-
US Physical Therapy Q3 revenue up 17.8% to $168.1M; EPS $0.48; reaffirms FY2025 guidance
Revenue $168.1M (+17.8% YoY); USPH Net Income $13.1M ($0.48 EPS) vs $6.6M ($0.39 EPS) prior year.
-
US Physical Therapy Q2 net income $12.4M; raises FY Adj EBITDA guidance to $93M-$97M
Q2 total revenue from PT ops $168.3M (+17.3%), IIP revenue $29.1M (+22.6%); record patient visits 1.56M (+16.7%).
-
USPH Q1 net income $9.9M ($0.80 EPS); revenue up 16.4% to $183.8M
Net income $9.9M ($0.80 EPS) vs $8.0M ($0.46) in Q1 2024.
-
USPH Q4 revenue up 14.2% to $180.4M; adjusted EBITDA $21.8M; dividend raised to $0.45
Q4 net revenue $180.4M (PT $153.8M + IIP $26.6M), vs $154.8M prior year; full-year revenue $671.3M.
-
USPH Q3: Adjusted EPS $0.55, record visits, IIP revenue up 30%, two acquisitions
Q3 GAAP EPS $0.39 (net income $6.6M); adjusted EPS $0.55 excluding $2.5M (net) clinic closure costs.
-
USPH closes $76.5M acquisition of 50% interest in Metro, 50-clinic operator
Paid ~$76.5M: $75M cash plus 18,358 shares of USPH common stock.
-
U.S. Physical Therapy acquires 50% stake in 50-clinic MSO for $76.5M
Purchase price $76.5M ($75M cash + $1.5M in USPH stock); sellers can earn up to $20M additional earnout based on performance.
-
USPH Q2 revenue up 8.5% to $143.5M; EPS $0.47 vs $0.64; guidance reaffirmed at $80-85M EBITDA
GAAP net income $7.5M ($0.47 diluted EPS) vs $10.9M ($0.64) in Q2 2023; share count up from May 2023 secondary offering.